hrcak mascot   Srce   HID

Pregledni rad
https://doi.org/10.13112/Pc.2013.4

Pharmacogenetics in clinical practice – Recommendations and guidelines

Nada Božina   ORCID icon orcid.org/0000-0001-6016-1699 ; Klinički zavod za laboratorijsku dijagnostiku, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
Lana Pejnović ; Klinički zavod za laboratorijsku dijagnostiku, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska

Puni tekst nije dostupan.

Sažetak
Variability in the eff ect of a drug can be partially explained by genetic diff erences. There are interindividual diff erences in metabolic
and transport capacity and detoxifi cation of drugs and other xenobiotics. Sensitivity to toxic eff ects partly depends on the genetic
polymorphism of metabolic enzymes of phase I and phase II. For clinical practice, the most important polymorphisms in phase I are
CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, and in phase II TPMT, UGT1A1, NAT2, SULT. The clearest impact have inactivating alleles
and alleles with increased CYP2C19 eff ect on the outcome of treatment with clopidogrel, as well as serious side eff ects to the use of
codeine in ultrarapid metabolizers of CYP2D6. Another signifi cant impact is observed in case of ineff ectiveness of antidepressants,
suicidality in ultrarapid metabolizers, and medication side eff ects in poor metabolizers of CYP2D6. Carriers of inactive CYP2C9 alleles
are at an increased risk of overdose with drug substrates, which can lead to intoxication with phenytoin, or bleeding in case of
coumarin anticoagulants or NSAIDs. There are guidelines for TPMT genotyping in case of thiopurine drug treatment, as well as
recommendations for the analysis of UGT1A1 for irinotecan therapy optimization and DPYD genotyping in case of the use of 5-fl uorouracil.
One of transport proteins recommended for genotyping is SLCO1B1 for better prevention of side eff ects in the use of statins.
Latest guidelines emphasize strong predisposition in the carriers of HLA-B * 5701 allele for the development of hypersensitivity to
abacavir. For better understanding of variable eff ectiveness of drugs in pediatric population, it is necessary, along with genetic
predisposition, to understand the diff erences in gene expression during growth and development, i.e. ontogenesis.

Ključne riječi
pharmacogenetics; drug toxicity; cytochrome P-450 enzyme system; TPMT; genetic testing

Hrčak ID: 119819

URI
https://hrcak.srce.hr/119819

[hrvatski]

Posjeta: 1.039 *